Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Allbirds Inc (BIRD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Allbirds Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Allbirds Inc trades at $3.43 (market cap $30.69M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 146.3× Allbirds Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BIRD | |
|---|---|---|
Market Cap | $4.49B | $30.69M |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $16.99 |
52-Week Low | $20.06 | $2.39 |
Enterprise Value | $3.69B | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BIRD (Smartbird) trades at $3.47, down 9.87% today, amid a complete pivot from footwear to AI infrastructure. The stock shows a bearish technical signal with negative cash flows and widening losses, though revenue decline has slowed. Recent news highlights the strategic rebranding and new CEO appointment, driving volatile price action. Analyst consensus remains cautious with 78.57% hold ratings, reflecting uncertainty around the business transformation.
Outlook is highly speculative given the radical business model shift. The AI pivot offers growth potential but carries execution risks amid persistent losses and negative equity. Investors face significant volatility as the company transitions, with success dependent on securing AI infrastructure contracts and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →
